Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 5/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | DRD5 | P21918 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.30 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2138873 | 0.80 | GABRA1 (0.42) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL6880352 | 0.77 | MT-CO2 (0.46) | MT-CO2 | |
| SCHEMBL248463 | 0.77 | ALDH1A1 (0.41) | PAX8 | |
| SCHEMBL20163048 | 0.72 | USP30 (0.42) | — | |
| SCHEMBL9805558 | 0.71 | GABRA1 (0.51) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL979761 | 0.71 | MAPT (0.49) | — | |
| SCHEMBL17091111 | 0.71 | GABRA5 (0.39) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL26932077 | 0.71 | GABRA5 (0.39) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL20163123 | 0.71 | TRPV1 (0.40) | PAX8 | |
| SCHEMBL7112682 | 0.70 | KCNH2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | HDAC2, HDAC1, HDAC3 | GABRA5 1580/4885GABRA1 1410/4885GABRG2 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.